GYRE Stockholders Approve Conversion of Series B Preferred Stock at Annual Meeting

Gyre Therapeutics announced that stockholders approved all proposals at its 2026 Annual Meeting of Stockholders held on June 10, 2026. A key approval was the issuance of common stock upon the conversion of the company's Series B Convertible Preferred Stock, in accordance with Nasdaq Listing Rule 5635(a).

Key Details

• Series B Preferred Stock Conversion: Stockholders approved the potential conversion of Series B Preferred Stock into common stock with 70,497,125 votes for.
• Director Elections: David M. Epstein, Ph.D., and Dan Weng, M.D., were elected as Class II directors to serve until the 2029 Annual Meeting.
• Other Approvals: The non-binding advisory vote on executive compensation was approved, and the appointment of Grant Thornton Zhitong Certified Public Accountants LLP as the independent auditor for 2026 was ratified.